Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 15/20 | 0.58 |
| ▸ | HTR1A | P08908 | 5/20 | 0.58 |
| ▸ | DRD2 | P14416 | 4/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21095168 | 1.00 | ADRA2C (0.63) | ADRA2CABCB1HTR1ADRD2ADRB2 | |
| SCHEMBL9068239 | 1.00 | ADRA2C (0.63) | ADRA2CABCB1HTR1ADRD2ADRB2 | |
| Hydrochloric Acid SCHEMBL8702416 | 0.99 | ADRA2C (0.61) | ADRA2CABCB1HTR1ADRD2ADRB2 | |
| Hydrochloric Acid SCHEMBL8702658 | 0.99 | ADRA2C (0.61) | ADRA2CABCB1HTR1ADRD2ADRB2 | |
| Hydrochloric Acid SCHEMBL8702425 | 0.99 | ADRA2C (0.61) | ADRA2CABCB1HTR1ADRD2ADRB2 | |
| SCHEMBL21094972 | 0.88 | ADRA2C (0.67) | ADRA2CABCB1HTR1AADRB2SLC6A2 | |
| SCHEMBL21094977 | 0.88 | ADRA2C (0.67) | ADRA2CABCB1HTR1AADRB2SLC6A2 | |
| SCHEMBL21094973 | 0.88 | ADRA2C (0.67) | ADRA2CABCB1HTR1AADRB2SLC6A2 | |
| SCHEMBL4174576 | 0.86 | ABCB1 (0.67) | ABCB1HTR1ADRD2HTR2A | |
| SCHEMBL21095162 | 0.86 | ABCB1 (0.67) | ABCB1HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA (UG) (haftungsbeschränkt) (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP11B2, CYP2D6 | ADRA2C 198/4885ABCB1 105/4885HTR1A 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.